Paper40904706
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.
Zhang L and 1 other. MedComm (2020), 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival. Papers, record 40904706. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40904706
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References250
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29587439 | NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29587439 | PubMed |
| 2 | 29937226 | LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. | Cell | 2018 | https://conductscience.org/library/papers/29937226 | PubMed |
| 3 | 36057027 | Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR). | Updates Surg | 2022 | https://conductscience.org/library/papers/36057027 | PubMed |
| 4 | 34069348 | Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34069348 | PubMed |
| 5 | 38030172 | Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion. | Anticancer Res | 2023 | https://conductscience.org/library/papers/38030172 | PubMed |
| 6 | 22127019 | Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. | Mol Ther | 2012 | https://conductscience.org/library/papers/22127019 | PubMed |
| 7 | 39159705 | Unleashing precision: A review of targeted approaches in pleural mesothelioma. | Crit Rev Oncol Hematol | 2024 | https://conductscience.org/library/papers/39159705 | PubMed |
| 8 | 34363903 | The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance. | Cancer Lett | 2021 | https://conductscience.org/library/papers/34363903 | PubMed |
| 9 | 26078352 | Reactive oxygen species a double-edged sword for mesothelioma. | Oncotarget | 2015 | https://conductscience.org/library/papers/26078352 | PubMed |
| 10 | 32226547 | The biological implications of Yin Yang 1 in the hallmarks of cancer. | Theranostics | 2020 | https://conductscience.org/library/papers/32226547 | PubMed |
| 11 | 24094913 | Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. | J Thorac Cardiovasc Surg | 2014 | https://conductscience.org/library/papers/24094913 | PubMed |
| 12 | 33485464 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33485464 | PubMed |
| 13 | 31367541 | A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. | Transl Lung Cancer Res | 2019 | https://conductscience.org/library/papers/31367541 | PubMed |
| 14 | 28599887 | Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/28599887 | PubMed |
| 15 | 37748190 | A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/37748190 | PubMed |
| 16 | 27418105 | Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages. | J Thorac Oncol | 2016 | https://conductscience.org/library/papers/27418105 | PubMed |
| 17 | 30338612 | Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. | Genes Chromosomes Cancer | 2018 | https://conductscience.org/library/papers/30338612 | PubMed |
| 18 | 40582407 | Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. | J Thorac Oncol | 2025 | https://conductscience.org/library/papers/40582407 | PubMed |
| 19 | 18543326 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. | Cancer | 2008 | https://conductscience.org/library/papers/18543326 | PubMed |
| 20 | 39495618 | Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study. | Asia Pac J Clin Oncol | 2024 | https://conductscience.org/library/papers/39495618 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942183 | Diaphragmatic Reconstruction with StratticeTM Biologic Mesh After Thoracic Oncologic Resection: A 10-Year Single-Center Retrospective Cohort Study. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42942183 | PubMed |
| 41982680 | MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/41982680 | PubMed |
| 41510382 | Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41510382 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40904706
GET https://conductscience.org/api/papers/v1/40904706/references?page=2